Compare Enact Holdings Inc (ACT) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs BioNano Genomics Inc — how do they compare? Enact Holdings Inc trades at $49.49 (market cap $6.75B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Enact Holdings Inc is far larger — about 494.1× BioNano Genomics Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ACT | BNGO | |
|---|---|---|
Market Cap | $6.75B | $13.66M |
Sector | Technology | Health |
52-Week High | $49.12 | $4.92 |
52-Week Low | $34.93 | $1.06 |
Enterprise Value | $7.05B | $16.26M |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.54, up 2.14% today, near the consensus price target of $49.00. The stock shows strong profitability with a net income margin of 54.51% and a P/E ratio of 10.36, indicating potential undervaluation. Recent Q2 2026 earnings beat estimates at $1.26 per share. Technical indicators signal a bullish trend, though RSI levels suggest overbought conditions. The company maintains stable dividends, with a $0.24 payout scheduled for September 2026.
Outlook is cautiously optimistic with solid fundamentals and analyst support, but risks include reliance on steady earnings growth and market volatility. The stock offers value with room for upside if earnings momentum continues, though overbought technicals may prompt short-term consolidation.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
